Investment
Features
FeesSafety
Academy
More
Pluang+

Compare GSK plc (GSK) vs Heron Therapeutics Inc (HRTX) Price & Performance

Heron Therapeutics IncTrade

Price performance (Past 24H)

Key statistics

GSK plc vs Heron Therapeutics Inc — how do they compare? GSK plc trades at $50.39 (market cap $102.60B), while Heron Therapeutics Inc trades at $0.35 (market cap $61.47M). The key difference: GSK plc is far larger — about 1669.1× Heron Therapeutics Inc's market cap, and GSK plc pays a 3.57% dividend while Heron Therapeutics Inc pays none. Which is the better fit depends on your goals.

GSKHRTX
Market Cap
$102.60B$61.47M
Sector
HealthHealth
52-Week High
$61.18$1.49
52-Week Low
$38.22$0.32
Enterprise Value
$123.04B$168.21M
Dividend Yield
3.57%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

GSK plc

GSK trades at $50.30, down 3.57% today, with a bearish technical signal from moving averages. The company reported strong Q2 2026 earnings of $1.36 per share, beating estimates of $1.27, and announced a $2.52 billion cost-saving plan through 2029. Revenue growth remains steady at 5% constant currency, supported by vaccines and specialty medicines. Analyst consensus shows 31% buy ratings with 55% hold, indicating cautious optimism.

GSK's solid profitability and strategic cost initiatives support long-term growth, but near-term stock performance faces headwinds from bearish technicals and mixed analyst sentiment. Key risks include pipeline execution and regulatory challenges, while institutional ownership trends and recent FDA approvals provide stability. The current valuation at 16.02 P/E offers reasonable entry for patient investors.

Heron Therapeutics Inc

HRTX trades at $0.3152, down 4.54% today, amid bearish technical signals and mixed earnings. The stock shows a high gross margin of 70.07% but negative net income margins, with Q2 2026 missing revenue and EPS estimates. Recent news highlights patent litigation developments and quarterly results falling short of expectations, contributing to investor caution.

The outlook remains challenged by persistent losses and operational cash burn, though analyst consensus is strongly bullish with 94.74% buy ratings. Key risks include execution on product sales, competitive pressures, and reliance on financing activities to sustain operations amid negative profitability.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About GSK plc

In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.

Read more on GSK

About Heron Therapeutics Inc

Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.

Read more on HRTX